Plasma pharmacokinetics and distribution of ruxolitinib into skin following oral and topical administration in minipigs
- 1 November 2020
- journal article
- research article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 590, 119889
Abstract
No abstract availableKeywords
Funding Information
- Intel Corporation
This publication has 15 references indexed in Scilit:
- Usefulness of minipigs for predicting human pharmacokinetics: Prediction of distribution volume and plasma clearanceDrug Metabolism and Pharmacokinetics, 2016
- Population Pharmacokinetic Analysis of Orally‐Administered Ruxolitinib (INCB018424 Phosphate) in Patients With Primary Myelofibrosis (PMF), Post‐Polycythemia Vera Myelofibrosis (PPV‐MF) or Post‐Essential Thrombocythemia Myelofibrosis (PET MF)The Journal of Clinical Pharmacology, 2013
- The Pharmacokinetics, Pharmacodynamics, and Safety of Orally Dosed INCB018424 Phosphate in Healthy VolunteersThe Journal of Clinical Pharmacology, 2011
- Metabolism, Excretion, and Pharmacokinetics of [14C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in HumansDrug Metabolism and Disposition, 2010
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in MyelofibrosisNew England Journal of Medicine, 2010
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasmsBlood, 2010
- The JAK/STAT signaling pathwayJournal of Cell Science, 2004
- Determination of the Effect of Lipophilicity on the in vitro Permeability and Tissue Reservoir Characteristics of Topically Applied Solutes in Human Skin LayersJournal of Investigative Dermatology, 2003
- Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discoveryBiopharmaceutics & Drug Disposition, 2002
- The Jak-STAT pathwayMolecular Immunology, 2000